《藥理學現(xiàn)況》（Cophar）發(fā)表了權(quán)威、全面和系統(tǒng)的評論。Cophar幫助專家了解藥理學和藥物發(fā)現(xiàn)的最新進展，并提供清晰易讀的綜合信息。專家作者從今天出版的不斷擴大的信息量中注釋最有趣的論文，節(jié)省了寶貴的時間，并使讀者對重要領(lǐng)域有了深刻的了解。Cophar是當前意見和研究（Co+Re）系列期刊的一部分，是新的初級研究、開放獲取期刊、藥理學和藥物發(fā)現(xiàn)（Crphar）的當前研究的伙伴。Cophar將藥理學的主題分成主題部分，每一部分每年進行一次回顧。每個部分的空間大小與其重要性有關(guān)。主題包括神經(jīng)科學、心血管和腎臟、呼吸、肌肉骨骼、癌癥、免疫調(diào)節(jié)、抗感染、新技術(shù)、胃腸、內(nèi)分泌和代謝疾病。該雜志以愛思唯爾在科學出版方面的卓越聲譽和長期致力于傳播以改善人類健康為目標的可再生生物醫(yī)學研究為基礎。

Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases.The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.